DICE Therapeutics, Inc.

DICE Therapeutics, Inc. (DICE) priced its initial public offering on Sep 16, 2021 at $17.00 per share, within its $15.00–$17.00 range, raising $204M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $618.2M. BofA Securities was lead-left underwriter, joined by Leerink Partners and Evercore ISI. Fenwick & West advised the company and Cooley advised the underwriters.

DICE Therapeutics, Inc. is a biopharmaceutical company building a pipeline of oral therapeutic candidates for chronic diseases, initially in immunology. Its DELSCAPE platform is designed to discover selective oral small molecules that modulate protein-protein interactions.

Status

IPO

Ticker

DICE

Exchange

Nasdaq Global Market

Priced

Sep 16, 2021

IPO price

$17.00

Price range

$15.00–$17.00

Raised

$204M

Market cap at IPO price

$618.2M

First filed

Aug 25, 2021

Underwriters

BofA Securities, Leerink Partners and Evercore ISI

Company counsel

Fenwick & West

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.